HomeNDC LookupRxCUI directory › RxCUI 105592

Etoposide 50 MG Oral Capsule [Vepesid] — RxCUI 105592

RxNorm drug concept · Semantic branded drug
RxCUI 105592 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI105592
Official nameEtoposide 50 MG Oral Capsule [Vepesid]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVepesid 50 MG Oral Capsule; VP-16 50 MG Oral Capsule [Vepesid]
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Etoposide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Etoposide is a chemotherapy drug approved for two main cancers: small cell lung cancer and refractory testicular tumors — meaning testicular cancer that hasn't responded to other t...
  • What exactly is etoposide being used to treat in my case?
  • The most common things people experience are low blood counts — which means a higher risk of infection and bleeding — nausea, hair loss, fatigue, and appetite changes. Nausea is us...
  • What side effects should I actually expect?
📖 Read our full Etoposide guide →

🕸️ Concept Web — How Etoposide 50 MG Oral Capsule [Vepesid] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Etoposide 50 MG Oral Capsule [Vepesid] RxCUI 105592

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Etoposide 4179
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vepesid 203058
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Etoposide Oral Capsule 372132
    • Etoposide Oral Product 1157929
    • Etoposide Pill 1157930
    • Etoposide Oral Capsule [Vepesid] 366233
    • Vepesid Oral Product 1187878
    • Vepesid Pill 1187879
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Etoposide 50 MG Oral Capsule SCD · 197687
  • Etoposide 50 MG SCDC · 315913
  • Etoposide Oral Capsule SCDF · 372132
  • Etoposide Oral Product SCDG · 1157929
  • Etoposide Pill SCDG · 1157930

Brand-Name Concepts

  • Etoposide 50 MG [Vepesid] SBDC · 564107
  • Etoposide Oral Capsule [Vepesid] SBDF · 366233
  • Vepesid Oral Product SBDG · 1187878
  • Vepesid Pill SBDG · 1187879
  • Vepesid BN · 203058

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 105592 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69238-2811-02 20 CAPSULE in 1 CARTON (69238-2811-2) VePesid Amneal Pharmaceuticals NY LLC 2026-05-15
Observed labelers: Amneal Pharmaceuticals NY LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.